Intensity Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing intratumoral cancer therapies led by INT230-6. Form 8-K reports furnish operating results, financial-condition updates, investor-presentation materials, and clinical-development summaries tied to the company’s non-covalent drug-conjugation platform and oncology studies.
The filing record also covers capital-structure and public-company matters, including an at-the-market common stock offering program, amendments related to a reverse stock split, Nasdaq minimum-bid-price compliance, and modifications to security-holder rights. Proxy materials describe annual meeting proposals, board elections, independent auditor ratification, and amendments to equity compensation and employee stock purchase plans.
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.544 million, compared with $2.671 million a year earlier. Research and development expense was $2.429 million versus $1.553 million; general and administrative expense was $1.194 million versus $1.180 million. Cash and cash equivalents were $8.494 million as of September 30, 2026. Third-quarter net proceeds under its at-the-market facility were $1.5 million; nine-month net proceeds were $3.2 million.
New patient enrollment activities resumed in a limited number of U.S. sites in Phase 3 INVINCIBLE-3 during the third quarter, under an FDA-reviewed amended protocol. Documentation for restarting in the EU and Canada is in process. Phase 2 INVINCIBLE-4 enrollment and treatment resumed in July 2026, with complete enrollment targeted by the end of 2027.
Preliminary INVINCIBLE-4 data from 14 patients, seven in each cohort, showed pathological complete response rates of 71% with INT230-6 and 42% with standard of care alone, and a 44% reduction in grade 3 adverse events in Cohort A versus Cohort B. The Swiss Cancer Institute established an independent data monitoring board to review safety data and images of newly treated patients; the company plans an update upon completion of the review in the first quarter of 2027.
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.544 million, versus $2.671 million in 2025; nine-month net loss was $8.985 million, versus $8.555 million. It has not generated product-sales revenue. Quarterly research and development expense was $2.429 million, compared with $1.553 million.
Cash and cash equivalents were $8.494 million as of September 30, 2026, and operating activities used $6.666 million during the nine months ended that date. Up to $56.9 million remained available under the at-the-market sales agreement as of September 30, 2026. Management says operations depend on additional capital, which is outside its control, and believes substantial doubt exists about continuing as a going concern; the company has no committed external funding source.
Enrollment in the 333-patient INVINCIBLE-3 Phase 3 study resumed at a limited number of U.S. sites in the third quarter after a funding-related pause. INVINCIBLE-4 treatment restarted in July 2026 after a protocol amendment; the company is targeting enrollment completion by the end of 2027. Preliminary data from the first 14 patients, seven per cohort, showed pathological complete response rates of 71% in Cohort A with INT230-6 and 42% in Cohort B receiving standard of care.
Intensity Therapeutics reported second-quarter 2026 results and highlighted progress in its late-stage oncology pipeline. The company is resuming enrollment at select U.S. sites in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial under an FDA-reviewed amended protocol, after a prior pause tied to funding constraints. In the Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer study, preliminary data from 14 patients showed a 71% pathological complete response rate with INT230-6 plus standard-of-care (Cohort A) versus 42% with standard-of-care alone (Cohort B), and a 44% reduction in grade 3 adverse events in Cohort A.
For the quarter ended June 30, 2026, research and development expenses were $1.8 million and general and administrative expenses were $1.3 million, leading to a net loss of $3.0 million or $1.11 per share. For the first six months of 2026, net loss was $5.4 million. Cash and cash equivalents totaled $9.5 million as of June 30, 2026. The company established a $60 million at-the-market facility and raised net proceeds of $1.6 million in the second quarter, with an additional $1.3 million raised after quarter-end.
Intensity Therapeutics, Inc. reported no revenue and continued operating losses for the quarter and six months ended June 30, 2026, reflecting its status as a late-stage clinical biotechnology company. Total assets were $11.5 million, including $9.5 million of cash and cash equivalents, down from $11.9 million at year-end 2025. Net loss was $3.0 million for the quarter and $5.4 million year-to-date, with an accumulated deficit of $83.8 million.
Research and development expenses were $1.8 million for the quarter and $3.0 million year-to-date, as the company funds its INVINCIBLE-3 Phase 3 soft tissue sarcoma study and INVINCIBLE-4 Phase 2 triple-negative breast cancer study. INVINCIBLE-3 enrollment was previously paused for funding reasons but limited U.S. enrollment activities have been restarted under an amended protocol. INVINCIBLE-4 enrollment resumed after a dosing adjustment, supported by preliminary data showing higher pathological complete response rates when INT230-6 is added to standard of care.
The company disclosed that it expects to incur substantial losses for the foreseeable future and stated there is substantial doubt about its ability to continue as a going concern without additional capital. Operations are being financed primarily through equity, including an at-the-market facility under which it has raised $13.1 million to date and can sell up to an additional $58.4 million of common stock.
Intensity Therapeutics, Inc. reported that director Thomas I H Dubin was granted a stock option to acquire 5,500 shares of Common Stock at an exercise price of $4.90 per share. The option expires on July 16, 2036 and will vest in four equal annual installments beginning July 16, 2026, subject to his continued service with the company. Following this grant, he directly holds options for 5,500 shares.
Intensity Therapeutics director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments starting July 16, 2026, subject to continued service.
Intensity Therapeutics, Inc. director Mark A. Goldberg received a grant of stock options covering 5,500 shares of common stock. The options have an exercise price of $4.90 per share, expire on 2036-07-16, and are held directly. They will vest in four equal annual installments beginning on July 16, 2026, subject to his continued service.
Intensity Therapeutics, Inc. reported that director Emer Leahy received a grant of stock options covering 5,500 shares of common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2026, subject to continued service, and expire July 16, 2036, leaving Leahy with options on 5,500 shares in total.
Intensity Therapeutics, Inc. reported an option grant to Principal Accounting Officer John M. Wesolowski for 11,000 stock options to buy common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2027 and expire July 16, 2036.
Intensity Therapeutics granted its Chief Financial Officer, Joseph Talamo, a stock option for 34,000 shares of Common Stock on July 16, 2026. The option has a $4.90 per-share exercise price and expires on July 16, 2036.
According to the terms, the option will vest in four equal annual installments beginning July 16, 2027, conditioned on his continued service with the company. Following this grant, Talamo holds 34,000 stock options directly.